We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Gsk Plc | LSE:GSK | London | Ordinary Share | GB00BN7SWP63 | ORD 31 1/4P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
3.00 | 0.22% | 1,342.50 | 1,340.00 | 1,340.50 | 1,345.00 | 1,335.50 | 1,338.00 | 3,344,130 | 16:35:12 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | 30.33B | 4.93B | 1.1889 | 11.28 | 55.52B |
Date | Subject | Author | Discuss |
---|---|---|---|
20/4/2009 08:45 | GlaxoSmithKline on Monday said it's paying at least $2.9 billion in cash to buy privately-held Stiefel Laboratories. | miata | |
20/4/2009 08:18 | up to £11.00+ in my opinion, buy confirmed on britishbulls.com | thebull3 | |
20/4/2009 06:28 | from Bloomberg ... GlaxoSmithKline PLC (GSK LN): The world's second-biggest drugmaker may be near an agreement to acquire Stiefel Laboratories Inc. for about $3 billion, the Wall Street Journal reported on its Web site, without saying where it got the information. The shares rose 3 pence, or 0.3 percent, to 1,038 pence. | analyzer | |
18/4/2009 18:40 | Amended 1171 - adr's indicate we should open higher on Mon! | sat69 | |
18/4/2009 17:45 | Suspect range change due, think we go higher this week, | chutes01 | |
18/4/2009 07:27 | Yesterday harvested the full premium on my written april 880 put option . I have high hopes that the written may and june 880 put options will also be succesful. I feel tempted to go forward further in time for more option writing but think I wait for results first, even though that may mean a price jump and lesser premium. | harvester | |
18/4/2009 06:42 | And judging by the adr's it looks like we'll be opening HIGHER on Monday. With results due on Wednesday though, the trading range is about to change, but to what....? | sat69 | |
17/4/2009 22:40 | In and out like a fiddler's elbow - 3 times previously I have said "get in at 1000ish" - does anyone listen? Yeah - no brainer indeed! If you haven't made cash on GSK over the last 6 weeks, then I would give up now! | eisler | |
17/4/2009 19:01 | Position closed - time to wait for £10 again! | sat69 | |
15/4/2009 10:50 | Eisler.....many here have bought in at £10. No brainer. | oilgetmecoat | |
15/4/2009 10:42 | Don't want to say "told you so" but..."told you so" | eisler | |
15/4/2009 07:33 | Rising nicely. Back in profit but hope I can hang on till at least 1050p this time! | sat69 | |
14/4/2009 08:19 | Q1 results next week - GSK always please! | sat69 | |
14/4/2009 08:11 | so am i. this should be the floor | juju43 | |
14/4/2009 07:58 | Back in again - £10. | sat69 | |
08/4/2009 16:34 | Eisler - You'll be able to get in at £10 again soon - maybe tomorrow? | sat69 | |
04/4/2009 07:50 | The Israeli pharma firm Teva has been touted as being a beneficiary of tighter medicare spending. Why buy expensive Glaxo when you can by cheaper generic drugs?May buy some when they next drop(usually when Israel looks like it's up the creek) to hedge my Gsk holding. I think that is what Buffett has done | spondon2 | |
04/4/2009 07:22 | Eisler - you are missing the point - harvester WROTE put options - he will pocket the full premium. | alphorn | |
03/4/2009 21:56 | A cracking coupla weeks of in-and-out with GSK - £1.6k in the coffers - so much for the "875p here we come" merchants! What bit of "get in at £10" did they not understand? Right, second chance. If you see GSK touch 1000-1020, get in - meaning buy them - that means BUY them...i.e. when the little box on your screen says "buy or sell" - select the "buy" option... Christ - look at the graph - it aint rocket science! But as ever, DYOR, IMHO, CYA and good luck! | eisler | |
03/4/2009 16:35 | Ah well, at least you can look forward to receiving your divi next week! | sat69 | |
03/4/2009 16:29 | Or maybe not! | kingsdock | |
03/4/2009 07:47 | GSK was upgraded to outperform from in-line by Cazenove, with the broker seeing an attractive risk profile at an attractive valuation. The broker also said there's upside from its pipeline, citing the drug Avodart for prostate cancer prevention which could add 500 million pounds onto the broker's 2013 sales forecasts and lift earnings by around 5%. Should help th share price today | kingsdock | |
01/4/2009 16:42 | How many pence/share is the divi? | spondon2 | |
31/3/2009 09:17 | Breakout started. | chutes01 |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions